VENTURA COUNTY
HEALTH CARE PLAN

Prior Authorization DRUG Guidelines

Ampyra(dalfampridine)

Effective Date: 12/20/11

Date Developed: 12/20/11 by Albert Reeves MD Last

Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19

(Archived 1/22/19)

Ampyra is a Potassium Channel Blocker which improves conduction in focally demyelinated axons by delaying repolarization and prolonging the duration of action potentials

Authorization Criteria:

treatment to improve walking in multiple sclerosis (MS) patients

Note: VCHCP requires that Ampyra (dalfampridine)be prescribed by a Neurologist or MS Specialist.

Dosing: **Multiple sclerosis:** Oral: 10 mg every 12 hours (maximum daily dose: 20 mg)

Note: Do not administer double or extra doses if a dose is missed.

How Supplied: 10 mg extended release tablet

Precautions: seizures (and contraindicated with a history of seizures or renal impairment)

DRUG Interactions: The following medications may increase the serum level of dalfampridine: cimetidine, metformin, quinidine

.

REFERENCES

1. Feret B, "Fampridine-SR: A Potassium-Channel Blocker for the Improvement of Walking Ability in Patients With MS," *Formulary*, 2009, 44:293-9.

2. Korenke AR, Rivey MP, and Allington DR. "Sustained-Release Fampridine for Symptomatic Treatment of Multiple Sclerosis," *Ann Pharmacother*, 2008, 42(10):1458-65.

3. Goodman AD, Brown TR, Krupp LB, et al, "Sustained-Release Oral Fampridine in Multiple Sclerosis: A Randomised, Double-Blind, Controlled Trial," *Lancet*, 2009, 373(9665):732-8.

4. Goodman AD, Brown TR, Edwards KR, et al, "A Phase 3 Trial of Extended Release Oral Dalfampridine in Multiple Sclerosis," *Ann Neurol*, 2010, 68(4):494-502

5. Korenke AR, Rivey MP, and Allington DR. "Sustained-Release Fampridine for Symptomatic Treatment of Multiple Sclerosis," *Ann Pharmacother*, 2008, 42(10):1458-65. [PubMed 18780812]

Revision History:

Date Reviewed/No Updates: 1/16/13 by A. Reeves, MD
Date Approved by P&T Committee: 1/31/12; 1/29/13
Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
Date Approved by P&T Committee: 1/28/14
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 7/23/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/Archived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Archived – check ESI